Correction for Serebruany et al., Circulation 108 (8) 939-944.

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Search for Related Content

(Circulation. 2003;108:3165.)
© 2003 American Heart Association, Inc.

Correction

An extract of the first 100% of the full text is provided, because this article has no abstract.

In the article, "Platelet/Endothelial Biomarkers in Depressed Patients Treated With the Selective Serotonin Reuptake Inhibitor Sertraline After Acute Coronary Events: The Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy" by Serebruany et al, which appeared in the August 26, 2003, issue of the journal (Circulation. 2003;108:939–944), some information was inadvertently omitted from the conflict-of-interest disclosure footnote. The following disclosures are added:

Dr Califf has received research support from and served as a consultant for Pfizer (all proceeds donated to Duke University). Dr O’Connor has received research support from and has consulted for Pfizer, GlaxoSmithKline, Eli Lilly, and Forest Pharmaceuticals, and holds patents for selective serotonin reuptake inhibitor research.